About: Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 August 1993

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 1993 (uk) article scientifique publié en 1993 (fr) im August 1993 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'agostu de 1993 (ast) scientific article published on 01 August 1993 (en)
publication date	wds:Q72892032-2752255C-3CD1-4E44-A039-A2447887BF52
publication date	1993-08-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q72892032-B24F4149-2D08-4CAF-A793-D4C795AA64E1
language of work or name	English
author name string	wds:Q72892032-1F3DBF60-0C03-47C9-83C4-EBDEF8D8F86F wds:Q72892032-30F6CCC0-D22E-4712-A83C-72BBD15BDB5B wds:Q72892032-3BFE1449-5287-4266-9D2A-646F22D7B3E8 wds:Q72892032-9617A432-B005-4F70-ACFA-EB0C52C93656 wds:Q72892032-A9D29796-D16B-4744-8B25-292DDF940447 wds:Q72892032-CC56A319-0997-4EE7-979F-564B01DF57A0 wds:Q72892032-F567E7D7-9EF1-455A-84AA-8FF1BA0BB319
author name string	D Glotz P Druet J Bariety A Francois J P Haymann N Sansonetti V Menoyo-Calonge
rdfs:label	Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (nl) Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients (en)
skos:prefLabel	Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (nl) Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients (en)
name	Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (nl) Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients (en)
title	wds:Q72892032-06CB8325-758B-426C-A78A-B7FC9A7A8C75
title	Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients (en)
page(s)	wds:Q72892032-28E02484-0949-458E-890C-EF447BF72A49
page(s)	335-337
instance of	wds:Q72892032-291ACA23-07C8-4B71-AAB7-A4EFE1BBA98C
instance of	scholarly article
PubMed ID	wds:Q72892032-9F187939-F13A-453E-A640-56052B20006C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8356587
PubMed ID	8356587
published in	wds:Q72892032-73EC5572-159A-48EB-A9BB-6B6FC9A0C3E4
published in	Transplantation
issue	wds:Q72892032-5D6AB03A-E697-4DB2-8440-2424F1C0CDE4
volume	wds:Q72892032-8B7B4ACF-3C7C-4AFC-88D7-A01A39285906
issue	2
volume	56
DOI	wds:Q72892032-DB22D064-67C2-4228-9B00-011DF13960EF
DOI	http://dx.doi.org/10.1097/00007890-199308000-00015
DOI	10.1097/00007890-199308000-00015
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72892032
is cites work of	Graft failure after allogeneic hematopoietic cell transplantation The humoral immune response towards HLA class II determinants in renal transplantation Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg) Intravenous immune globulins: an update for clinicians Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients Successful renal transplant outcome after intravenous gamma-globulin treatment of a highly sensitized pediatric recipient Treatment options and strategies for antibody mediated rejection after renal transplantation Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation Renal transplantation in high-risk patients Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production Immunobiologic consequences of assist devices Modern approaches to incompatible kidney transplantation C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts Cardiac transplantation across a positive prospective lymphocyte cross-match in sensitized recipients Desensitization for solid organ and hematopoietic stem cell transplantation Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation Mechanism of accommodation in a sensitized human leukocyte antigen transgenic murine cardiac transplant model Compatibility and kidney transplantation: the way to go. Translational research in kidney transplantation and the role of patient engagement Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results The effect of simvastatin on panel-reactive antibody and crossmatch positivity Effect of HMG-CoA reductase inhibitors on reduction of panel reactivity Impact of current management practices on early and late death in more than 500 consecutive cardiac transplant recipients Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match Use of intravenous immunoglobulin in sensitized LVAD recipients. [Immunomodulatory effects of intravenous immunoglobulins] Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates Use of intravenous immunoglobulin in organ transplantation for noninfectious indications Different responses of human anti-HLA and anti-alphagal antibody to long-term intravenous immunoglobulin therapy Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg. Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one's own HLA types, but may be masked by Fab complementarity-determining region peptide in the native sera Inhibition of HLA antibody cytotoxicity by intravenous immunoglobulin G F(ab')2 dimers, monomers, and monovalent F(ab) The current state of, and future prospects for, cardiac transplantation in children Humanized monoclonals and other biological initiatives Management of the highly HLA- sensitized patient. A novel role for intravenous gammaglobulin Mesenchymal stem cell transfusion for desensitization of positive lymphocyte cross-match before kidney transplantation: outcome of 3 cases Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report Variable in vitro inhibition of HLA-specific alloantibody-mediated cytotoxicity by intravenous human immunoglobulin Effect of high-dose intravenous immunoglobulin on suppression of alloantibodies against hla in highly sensitized transplant candidates. Desensitisation strategies in high-risk children before kidney transplantation.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software